Here's Why Abbott (ABT) Fell More Than Broader Market

Abbott (ABT) shares dropped 1.47% in the latest session, significantly underperforming the S&P 500's 0.29% decline, despite a 3.27% gain over the past month. The company is set to report earnings with consensus estimates forecasting a 7.44% EPS increase to $1.3 and 7.4% revenue growth to $11.42 billion. However, ABT trades at a premium valuation, with a Forward P/E of 26.4 and a PEG ratio of 2.58, both exceeding industry averages, and currently holds a Zacks Rank #3 (Hold).

Analysis

Abbott (ABT) recently exhibited underperformance, with its shares declining 1.47% against the S&P 500's milder 0.29% loss. This near-term weakness contrasts with its prior month's performance, where the stock gained 3.27%, outperforming both the broader S&P 500 and its own Medical sector, which lost 0.33%. Forward-looking consensus estimates anticipate solid growth, with upcoming quarterly earnings per share (EPS) projected at $1.30, a 7.44% year-over-year increase, and revenue at $11.42 billion, up 7.4%. Full-year estimates are also robust, projecting EPS growth of 10.28% and revenue growth of 6.5%. However, this positive outlook is tempered by several factors. Analyst EPS estimates have remained unchanged over the past 30 days, contributing to a neutral Zacks Rank #3 (Hold). Furthermore, the stock's valuation appears stretched, trading at a Forward P/E of 26.4, which is a significant premium to its industry's average of 18.45. Similarly, its PEG ratio of 2.58 is elevated compared to the industry average of 2.31, suggesting the expected growth is already reflected in the price.

Key Decisions for Investors

• Given the stock's premium valuation and the neutral Zacks Rank #3 (Hold), investors should consider that the strong projected earnings growth may already be priced in, suggesting a hold strategy pending the upcoming earnings release.
• Monitor the upcoming earnings report closely, as any failure to meet or exceed the high expectations for 7.4% revenue and 7.44% EPS growth could trigger a price correction due to the elevated Forward P/E and PEG ratios.
• Note the lack of upward analyst revisions in the last 30 days; a change in this trend following the earnings announcement could serve as a key signal for a potential re-rating of the stock.